Vasokinox

Vasokinox provides nitric oxide gas for endotracheopulmonary use in clinical settings. It supports vascular relaxation and oxygenation support during respiratory care. This medical gas is commonly used in hospitals for targeted pulmonary vasodilation. Vasokinox is supplied by Air Liquide Santé International.

Vasokinox is used to improve oxygenation in patients with hypoxic respiratory failure, particularly those with pulmonary hypertension. It is indicated for endotracheopulmonary administration to dilate pulmonary blood vessels and reduce vascular resistance. Healthcare professionals use it when conventional therapies are insufficient. This gas helps manage conditions where improved blood flow to the lungs is critical.

When administered, Vasokinox acts locally in the lungs to relax blood vessels, which may help improve oxygen exchange. Users typically observe changes in blood oxygen levels during treatment. The effects are generally rapid and localized to the pulmonary circulation. Monitoring is required to assess response and adjust therapy as needed.

Vasokinox should only be handled by trained medical personnel in controlled clinical environments. Proper ventilation and monitoring equipment are essential during administration. It is not intended for home or unsupervised use. Storage must comply with medical gas safety standards to prevent leaks or contamination.

Nitric oxide may interact with other pulmonary vasodilators or medications affecting blood pressure. Concurrent use with systemic vasodilators requires careful monitoring to avoid excessive hypotension. It is generally administered separately from other inhaled therapies to prevent cross-reactions. Alcohol and certain CYP inhibitors may alter metabolism but are not typically co-administered with nitric oxide.